Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas抗体聚合物药物偶联物，其药物与抗体比率增加：靶向CD38的纳米药物，用于复发性淋巴瘤的创新治疗Journal of Controlled ReleaseIF11.52025-05-210PRE
Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitorsCELL DEATH DISCOVERYIF72025-02-180OAAI
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomasLABORATORY INVESTIGATIONIF4.22022-09-014OAAI
3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K DegradersJOURNAL OF MEDICINAL CHEMISTRYIF6.82022-06-2416PRE
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell LymphomasMOLECULAR CANCER THERAPEUTICSIF5.52021-11-0210OAAI
Cell cycle and differentiation of Sca-1+ and Sca-1- hematopoietic stem and progenitor cellsCELL CYCLEIF3.42018-09-117OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向